Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHENEA: chemotherapy plus atezolizumab for stage IIIA-IIIB NSCLC with surgery-directed or chemoradiotherapy-directed continuation
2024-515984-68-00Phase 2Authorised
- Sponsor
- Fundación GECP
- Start
- May 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, paclitaxel and carboplatin in non-small cell lung cancer (NSCLC), sponsored by Fundación GECP. Primary endpoint: Progression-free survival rate at 18 months. Planned start May 2025; status: authorised.
02
Drugs
atezolizumabpaclitaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-515984-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515984-68-00.